Thymosin Alpha-1 vs LL-37

Overview

Thymosin alpha-1 and LL-37 are both peptides involved in immune function, but with different mechanisms and regulatory histories. Thymosin alpha-1 is approved as an immunomodulator in several countries (though not the US), while LL-37 is a naturally occurring human antimicrobial peptide being studied for therapeutic applications.

This comparison is relevant because both peptides are discussed in immune health contexts with different evidence bases and regulatory statuses.

Key Facts

Aspect	Thymosin Alpha-1	LL-37
Also Known As	Tα1, Zadaxin	Cathelicidin, CAP-18
Structure	28 amino acids	37 amino acids
Origin	Thymus gland	Human cathelicidin hCAP-18
Primary Action	Immunomodulation	Antimicrobial, immunomodulatory
FDA Status	Not approved	Not approved
Other Approvals	~35 countries	None

Structure and Origin

Aspect	Thymosin Alpha-1	LL-37
Amino Acids	28	37
Natural Source	Thymic tissue	Neutrophils, epithelial cells
N-terminus	Acetylated	Leucine
Molecular Weight	~3,108 Da	~4,493 Da

Thymosin Alpha-1 Background

• Originally isolated from bovine thymus (1970s)
• Synthetic version developed for therapy
• Part of the “thymosin fraction 5” research
• Immunomodulatory properties studied extensively

LL-37 Background

• Human cathelicidin antimicrobial peptide
• Cleaved from precursor hCAP-18
• Found in neutrophils, epithelia, wound fluid
• Part of innate immune defense

Mechanism Comparison

Aspect	Thymosin Alpha-1	LL-37
Primary Action	T-cell modulation	Direct antimicrobial
Secondary Action	Dendritic cell activation	Immunomodulation
Innate Immunity	Enhancement	Direct effector
Adaptive Immunity	Enhancement	Indirect effects

Thymosin Alpha-1 Mechanisms

1. T-Cell Effects

   • Promotes T-cell maturation
   • Enhances T-cell function
   • Restores immune balance

2. Dendritic Cell Activation

   • Stimulates dendritic cells
   • Improves antigen presentation
   • Enhances immune surveillance

3. Cytokine Modulation

   • Modulates inflammatory cytokines
   • May shift toward Th1 response
   • Balances immune response

LL-37 Mechanisms

1. Direct Antimicrobial

   • Disrupts bacterial membranes
   • Broad-spectrum activity
   • Active against bacteria, fungi, viruses

2. Immunomodulation

   • Chemoattractant for immune cells
   • Modulates cytokine release
   • Promotes wound healing

3. LPS Neutralization

   • Binds lipopolysaccharide
   • Reduces inflammatory response
   • Prevents sepsis cascade

Evidence Comparison

Factor	Thymosin Alpha-1	LL-37
Human Trials	Multiple	Few
Approvals	~35 countries	None
Indications Studied	Hepatitis B/C, cancer, sepsis	Infections, wound healing
Evidence Quality	Moderate	Low-Moderate

Thymosin Alpha-1 Clinical Evidence

Condition	Evidence Level	Notes
Hepatitis B	Moderate	Approved indication (some countries)
Hepatitis C	Moderate	Studied as adjunct therapy
Cancer immunotherapy	Low-Moderate	Adjunct use studied
Sepsis	Low-Moderate	Some trials completed
Vaccine adjuvant	Low	Preliminary research

LL-37 Research Evidence

Area	Evidence Level	Notes
Antimicrobial activity	Moderate (in vitro)	Well-established mechanism
Wound healing	Low	Preclinical promising
Inflammatory conditions	Low	Early research
Therapeutic use	Very Low	No completed human trials

Clinical Applications

Thymosin Alpha-1 Approved Uses (Non-US)

Indication	Countries	Notes
Chronic Hepatitis B	Multiple (Asia, Europe)	Primary indication
Chronic Hepatitis C	Some countries	Combination therapy
Immunodeficiency	Limited	Orphan uses

LL-37 Research Applications

Application	Status	Notes
Topical infections	Preclinical	Wound applications
Respiratory infections	Early research	Nebulized delivery
Cancer	Very early	Some anticancer research

Side Effect Profiles

Thymosin Alpha-1

Effect	Frequency	Notes
Injection site reactions	Common	Typical for peptide
Flu-like symptoms	Occasional	Immune activation
Fever	Occasional	Dose-dependent
Generally well-tolerated	Yes	Extensive safety data

LL-37

Effect	Frequency	Notes
Local inflammation	Possible	Pro-inflammatory potential
Systemic effects	Unknown	Limited human data
Hemolysis (high doses)	Possible	Seen in some studies

Administration

Aspect	Thymosin Alpha-1	LL-37
Typical Route	Subcutaneous	Variable (research)
Stability	Good	Degradation concerns

Regulatory Status

Aspect	Thymosin Alpha-1	LL-37
FDA Status	Not approved	Not approved
Orphan Drug (US)	Yes (certain conditions)	No
International Approvals	~35 countries	None
Brand Name	Zadaxin	N/A
US Availability	Compounding/research	Research only

Why Not FDA Approved

Thymosin Alpha-1:

• FDA requires new trials to US standards
• Commercial pathway unclear
• Available through compounding pharmacies

LL-37:

• Still in early research phase
• Stability and delivery challenges
• No completed Phase 2/3 trials

Comparison in Immune Support Context

Factor	Thymosin Alpha-1	LL-37
Immune Enhancement	Primary purpose	Secondary effect
Direct Pathogen Killing	No	Yes
T-Cell Support	Primary mechanism	Indirect
Infection Response	Adjunctive	Direct defense
Clinical Experience	Decades	Minimal

Quality and Sourcing

Thymosin Alpha-1

Source	Quality
Pharmaceutical (Zadaxin)	High (where available)
Compounding (US)	Variable
Research chemical	Variable

LL-37

Source	Quality
Research suppliers	Variable
Custom synthesis	Expensive
Stability issues	Common

Summary

Factor	Thymosin Alpha-1	LL-37
Structure	28 amino acids	37 amino acids
Primary Action	Immunomodulation	Antimicrobial
Evidence Level	Moderate	Moderate
Regulatory Status	Approved (~35 countries)	Not approved
US Availability	Compounding	Research only
Safety Data	Extensive	Limited
Clinical Experience	Decades	Minimal

Key Takeaways

1. Different mechanisms: Thymosin alpha-1 modulates immune cells; LL-37 directly kills pathogens
2. Thymosin alpha-1 has approvals: Licensed in ~35 countries but not FDA-approved
3. LL-37 is earlier in development: No clinical approvals anywhere
4. Thymosin alpha-1 has more safety data: Decades of clinical use internationally
5. LL-37 has antimicrobial activity: Unique direct pathogen-killing capability
6. US access differs: Thymosin alpha-1 available through compounding; LL-37 research-only
7. Different use cases: Thymosin alpha-1 for immune support; LL-37 potentially for infections
8. Quality varies: Both require careful sourcing

---

This comparison is for educational purposes only. Neither peptide is FDA-approved. Thymosin alpha-1 is approved in other countries. LL-37 is a research compound.